Staining patterns of p53 immunohistochemistry and their biological significance in colorectal cancer

Journal of Pathology

Volumn 190, Issue 4, 2000, Pages 450-456

  Kaserer, Klaus ^b   Schmaus, Judith ^c   Bethge, Ulrike ^c   Migschitz, Brigitte ^c   Fasching, Sabine ^c   Walch, Axel ^a   Herbst, Friedrich ^c   Teleky, Bela ^c   Wrba, Fritz ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c NONE

Author keywords

Colonic adenocarcinoma; Immunohistochemistry; mdm 2; p53; SSCP

Indexed keywords

ADULT; AGED; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; SEQUENCE ANALYSIS; STAINING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENE SILENCING; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION;

EID: 0034098827     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(200003)190:4<450::AID-PATH545>3.0.CO;2-8     Document Type: Article

References (29)

1. Harris CC. Structure and function of the p53 tumour suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996; 88: 1442-1455.
2. Wynford Thomas D. p53 in tumour pathology: can we trust immunohistochemistry? J Pathol 1992; 166: 329-330.
3. Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry? revisited! J Pathol 1994; 172: 1-4.
4. Baas IO, Mulder JWR, Offerhaus JW, et al. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994; 172: 5-12.
5. Costa A, Marasca R. Valentinis B, et al. p53 gene mutations in relation to p53 nuclear protein accumulation in colorectal cancers. J Pathol 1995; 176: 45-53.
6. Bertorelle R, Esposito G, DelMistro A, et al. Association of p53 gene and protein alterations with metastases in colorectal cancer. Am J Surg Pathol 1995; 19: 463-471.
7. Ambros RA, Ross JS, Kallakury BVS, et al. p53 gene status in endometrial carcinomas showing diffuse positivity for p53 protein by immunohistochemical analysis. Mod Pathol 1995; 8: 441-445.
8. Hamelin R, Laurent-Puig P, Olschwang S, et al. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994; 106: 42-48.
9. Hurlimann J, Chaubert P, Benhattar J. p53 gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques. Mod Pathol 1994; 7: 423-428.
10. Wu X, Bayle JH, Olson D, et al. The p53-MDM2 autoregulatory feedback loop. Gen Dev 1993; 7: 1126-1132.
11. Williams AC, Miller CJ, Collard TJ, et al. Mutant p53 is not fully dominant over endogenous wild type p53 in a colorectal adenoma cell line as demonstrated by induction of MDM2 protein and retention of a p53 dependent G1 arrest after gamma irradiation. Oncogene 1995; 11: 141-149.
12. Price BD, Park SJ. DNA damage increases the levels of mdm2 messenger RNA in wt p53 human cells. Cancer Res 1994; 54: 896-899.
13. Piette J, Neel H, Maréchal V. Mdm2: keeping p53 under control. Oncogene 1997; 15: 1001-1010.
14. Oliva MR, Ripoli F, Muniz P, et al. Genetic alterations and oxidative metabolism in sporadic colorectal tumours from a Spanish community. Mol Carcinog 1997; 18: 232-243.
15. Becker I, Becker KF, Röhrl MH, et al. Single cell mutation analysis of tumours from stained histologic slides. Lab Invest 1996; 75: 801-807.
16. Bodner SM, Minna JD, Jensen SM, et al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 mutation. Oncogene 1992; 7: 743-749.
17. Ogden GR, Kiddie RA, Lunny DP, et al. Assessment of p53 protein expression in normal, benign, and malignant oral mucosa. J Pathol 1992; 166: 389-394.
18. Soong R, Robbins PD, Dix BR, et al. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol 1996; 27: 1050-1055.
19. Calzolari A, Chiarelli I, Bianchi S, et al. Immunohistochemical vs. molecular biology methods: complementary techniques for effective screening of p53 alterations in head and neck cancer. Am J Clin Pathol 1997; 107: 7-11.
20. Burns JS, Blaydes JP, Wright PA, et al. Stepwise transformation of primary thyroid epithelial cells by a mutant Ha-ras oncogene: an in vitro model of tumour progression. Mol Carcinog 1992; 6: 129-139.
21. Rodrigues NR, Rowan A, Smith ME, et al. p53 mutations in colorectal cancer. PNAS 1990; 87: 7555-7559.
22. Lehman TA, Bennett WP, Metcalf RA, et al. p53 mutations, ras mutations, and p53 heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res 1991; 51: 4090-4096.
23. Shaulian E, Resnitzky D, Shifman O, et al. Induction of Mdm2 and enhancement of cell survival by bFGF. Oncogene 1997; 15: 2717-2725.
24. Bhatia K, Guttierez MI, Huppi K, et al. PCR detection of neutral CGA/CGG dimorphism in exon 6 of the human p53 gene. Nucleic Acid Res 1992; 20: 928-932.
25. Greenblatt MS, Bennet WP, Hollstein M, et al. Mutations in the p53 tumour suppressor gene: clues to cancer aetiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-4878.
26. O'Neil M, Campbell SJ, Save V. et al. An immunochemical analysis of mdm2 expression in human breast cancer and the identification of a growth regulated cross-reacting species p 170. J Pathol 1998; 186: 254-261.
27. Gorgoulis VG, Zoumpourlis V, Rassidakis GZ, et al. A molecular and immunohistochemical study of the mdm2 protein isoforms and p53 gene product in bronchogenic carcinoma. J Pathol 1996; 180: 129-137.
28. Ren ZP, Ponten F, Nister M, et al. Two distinct immunohistochemical patterns in human squamous-cell skin cancer, precursors and normal epidermis. Int J Cancer 1996; 69: 174-179.
29. Perry ME, Piette J, Zawadzki JA, et al. The mdm2 gene is induced in response to UV light in a p53 dependent manner. PNAS 1993; 90: 11623-11627.